Necrostatin-1

Name: Necrostatin-1
Brand: Selleck Chemicals
SKU: S8037
Rating: 5 (107 reviews)

For research use only.

Catalog No.S8037 Synonyms: Nec-1

107 publications

CAS No. 4311-88-0

Necrostatin-1 (Nec-1) is a specific RIP1 (RIPK1) inhibitor and inhibits TNF-α-induced necroptosis with EC50 of 490 nM in 293T cells. Necrostatin-1 also blocks IDO and suppresses autophagy and apoptosis.

Selleck's Necrostatin-1 has been cited by 107 publications

Cell, 2021, S0092-8674(21)00885-0

PubMed: 34363755 ( click the link to review the publication )

Nat Immunol, 2021, 22(9):1107-1117

PubMed: 34385713 ( click the link to review the publication )

Adv Sci (Weinh), 2021, 8(10):2004680

PubMed: 34026460 ( click the link to review the publication )

Haematologica, 2021, 10.3324/haematol.2020.259531

PubMed: 33406814 ( click the link to review the publication )

Oncogene, 2021, 10.1038/s41388-021-01869-4

PubMed: 34155344 ( click the link to review the publication )

Stem Cell Reports, 2021, S2213-6711(21)00158-2

PubMed: 33891868 ( click the link to review the publication )

Cancers (Basel), 2021, 13(2)E243

PubMed: 33440739 ( click the link to review the publication )

Free Radic Biol Med, 2021, 173:64-69

PubMed: 34252539 ( click the link to review the publication )

BMC Biol, 2021, 19(1):140

PubMed: 34325694 ( click the link to review the publication )

FASEB J, 2021, 35(5):e21561

PubMed: 33864423 ( click the link to review the publication )

J Mol Cell Cardiol, 2021, 150:65-76

PubMed: 33098823 ( click the link to review the publication )

Front Cell Dev Biol, 2021, 9:651360

PubMed: 33842478 ( click the link to review the publication )

Biomolecules, 2021, 11(2)153

PubMed: 33503908 ( click the link to review the publication )

Int J Mol Sci, 2021, 22(5)2702

PubMed: 33800107 ( click the link to review the publication )

Front Microbiol, 2021, 12:664353

PubMed: 34149651 ( click the link to review the publication )

Acta Pharmacol Sin, 2021, 10.1038/s41401-021-00749-7

PubMed: 34376811 ( click the link to review the publication )

Toxicol In Vitro, 2021, 73:105146

PubMed: 33737050 ( click the link to review the publication )

Eur J Histochem, 2021, 65(2)

PubMed: 34155879 ( click the link to review the publication )

Hum Cell, 2021, 10.1007/s13577-021-00557-5

PubMed: 34117611 ( click the link to review the publication )

Biochem Genet, 2021, 10.1007/s10528-021-10107-1

PubMed: 34327615 ( click the link to review the publication )

Mol Med Rep, 2021, 24(2)544

PubMed: 34080030 ( click the link to review the publication )

Immunohorizons, 2021, 5(2):90-101

PubMed: 33597177 ( click the link to review the publication )

Mol Neurobiol, 2021, 10.1007/s12035-021-02320-1

PubMed: 33634378 ( click the link to review the publication )

Transl Stroke Res, 2021, 10.1007/s12975-021-00888-3

PubMed: 33629276 ( click the link to review the publication )
Autophagy, 2021, 1-15

PubMed: 33629929 ( click the link to review the publication )

Sci Adv, 2020, 25;6(13):eaay9789

PubMed: 32232155 ( click the link to review the publication )

Part Fibre Toxicol, 2020, 17(1):46

PubMed: 32948194 ( click the link to review the publication )

Redox Biol, 2020, 38:101777

PubMed: 33166869 ( click the link to review the publication )

J Med Chem, 2020, 63(17):9838-9855

PubMed: 32809827 ( click the link to review the publication )

Cancers (Basel), 2020, 12(11)E3205

PubMed: 33143299 ( click the link to review the publication )

Cell Death Dis, 2020, 11(9):781

PubMed: 32951003 ( click the link to review the publication )

Cell Death Dis, 2020, 22;11(5):391

PubMed: 32444644 ( click the link to review the publication )

Mol Nutr Food Res, 2020, 1;e1901231

PubMed: 32476238 ( click the link to review the publication )

Oxid Med Cell Longev, 2020, 2020:1295382

PubMed: 33123307 ( click the link to review the publication )

Oxid Med Cell Longev, 2020, 4;2020:5021983

PubMed: 32322335 ( click the link to review the publication )

Oncogenesis, 2020, 9(10):94

PubMed: 33093450 ( click the link to review the publication )

Int J Mol Sci, 2020, 21(12)E4204

PubMed: 32545631 ( click the link to review the publication )

J Biol Chem, 2020, 1;295(18):6236-6248

PubMed: 32179652 ( click the link to review the publication )

Acta Pharmacol Sin, 2020, 10.1038/s41401-020-0376-8

PubMed: 32132657 ( click the link to review the publication )

Front Pharmacol, 2020, 11:812

PubMed: 32595496 ( click the link to review the publication )

Biochem Biophys Res Commun, 2020, 8;521(2):414-419

PubMed: 31672277 ( click the link to review the publication )

Med Sci Monit, 2020, 26:e919739

PubMed: 32019905 ( click the link to review the publication )

Biosci Biotechnol Biochem, 2020, 18;1-8

PubMed: 32419644 ( click the link to review the publication )

Blood Adv, 2020, 4(22):5666-5680

PubMed: 33211827 ( click the link to review the publication )

STAR Protoc, 2020, 1(1)100034

PubMed: 32793892 ( click the link to review the publication )

Cell Death Dis, 2020, 11(8):630

PubMed: 32801360 ( click the link to review the publication )

Cell Death Discov, 2020, 6:67

PubMed: 32793397 ( click the link to review the publication )

Cell Death Dis, 2020, 11(8):635

PubMed: 32801338 ( click the link to review the publication )
PLoS Pathog, 2020, 16(7):e1008473

PubMed: 32649716 ( click the link to review the publication )

Int J Oncol, 2020, 56(2):439-447

PubMed: 31894265 ( click the link to review the publication )

Cell Rep, 2020, 30(1):25-36

PubMed: 31914391 ( click the link to review the publication )

Sci Total Environ, 2020, 699:134296

PubMed: 31683218 ( click the link to review the publication )

J Clin Invest, 2019, 129(6):2431-2445

PubMed: 31081803 ( click the link to review the publication )

EMBO Rep, 2019, 20(10):e47840

PubMed: 31410978 ( click the link to review the publication )

Cell Death Differ, 2019, 10.1038/s41418-019-0274-0

PubMed: 30760873 ( click the link to review the publication )

Front Oncol, 2019, 9:436

PubMed: 31192135 ( click the link to review the publication )

Sci Rep, 2019, 9(1):2902

PubMed: 30814594 ( click the link to review the publication )

J Biol Chem, 2019, 10.1074/jbc.RA119.010379

PubMed: 31723031 ( click the link to review the publication )

Front Mol Neurosci, 2019, 12:222

PubMed: 31607859 ( click the link to review the publication )

Int J Mol Med, 2019, 43(2):967-979

PubMed: 30569134 ( click the link to review the publication )

Cell Transplant, 2019, 28(11):1358-1372

PubMed: 31370690 ( click the link to review the publication )

bioRxiv, 2019, 10.1101/537753

PubMed: None ( click the link to review the publication )

Mol Metab, 2019, 23:14-23

PubMed: 30837196 ( click the link to review the publication )

Oncotarget, 2019, 10(62):6678-6690

PubMed: 31803362 ( click the link to review the publication )

J Hepatol, 2018, 68(6):1228-1238

PubMed: 29408314 ( click the link to review the publication )

Nat Commun, 2018, 9(1):1680

PubMed: 29700283 ( click the link to review the publication )

Autophagy, 2018, 14(5):778-795

PubMed: 29171784 ( click the link to review the publication )

Clin Cancer Res, 2018, 24(23):6066-6077

PubMed: 30061362 ( click the link to review the publication )

Elife, 2018, 10.7554/eLife.40167

PubMed: 30561326 ( click the link to review the publication )

Oncogene, 2018, 37(29):4033-4045

PubMed: 29706658 ( click the link to review the publication )

Cell Death Dis, 2018, 9(6):679

PubMed: 29880840 ( click the link to review the publication )

Oncoimmunology, 2018, 7(6):e1431086

PubMed: 29872558 ( click the link to review the publication )
Mol Oncol, 2018, 10.1002/1878-0261.12422

PubMed: 30537101 ( click the link to review the publication )

Biochim Biophys Acta Mol Cell Res, 2018, 1865(3):522-531

PubMed: 29278689 ( click the link to review the publication )

J Immunol, 2018, 200(8):2826-2834

PubMed: 29563176 ( click the link to review the publication )

Am J Cancer Res, 2018, 8(8):1514-1527

PubMed: 30210920 ( click the link to review the publication )

Ann Biomed Eng, 2018, 46(7):1013-1025

PubMed: 29603044 ( click the link to review the publication )

Toxicology, 2018, 406-407:33-43

PubMed: 29860048 ( click the link to review the publication )

Am J Transl Res, 2018, 10(5):1357-1372

PubMed: 29887951 ( click the link to review the publication )

Int J Mol Med, 2018, 41(5):3051-3062

PubMed: 29436589 ( click the link to review the publication )

Int J Med Sci, 2018, 15(14):1648-1657

PubMed: 30588188 ( click the link to review the publication )

Cancer Commun (Lond), 2018, 38(1):43

PubMed: 29970185 ( click the link to review the publication )

Cancer Lett, 2017, 402:81-92

PubMed: 28576750 ( click the link to review the publication )

Cancer Lett, 2017, 381(1):96-103

PubMed: 27477897 ( click the link to review the publication )

Cell Death Dis, 2017, 8(5):e2765

PubMed: 28471454 ( click the link to review the publication )

Oncotarget, 2017, 8(26):43201-43217

PubMed: 28591723 ( click the link to review the publication )

Environ Sci Pollut Res Int, 2017, 24(1):215-225

PubMed: 27709431 ( click the link to review the publication )

Genes Chromosomes Cancer, 2017,

PubMed: 28177558 ( click the link to review the publication )

Cell Cycle, 2017, 16(4):348-359

PubMed: 27929749 ( click the link to review the publication )

Nat Commun, 2016, 7:10274

PubMed: 26817517 ( click the link to review the publication )

Autophagy, 2016, 12(10):1738-1758

PubMed: 27463126 ( click the link to review the publication )

Autophagy, 2016, 12(4):659-70

PubMed: 27050456 ( click the link to review the publication )

Cancer Res, 2016, 10.1158/0008-5472.CAN-16-0523

PubMed: 27302164 ( click the link to review the publication )

J Exp Clin Cancer Res, 2016, 8;35(1):192

PubMed: 27931237 ( click the link to review the publication )

Free Radical Biology and Medicine, 2016, S0891-5849(16)00114-3

PubMed: 27012422 ( click the link to review the publication )

Sci Rep, 2016, 6:24245

PubMed: 27095146 ( click the link to review the publication )
Oncol Rep, 2016, 36(2):1135-42

PubMed: 27349281 ( click the link to review the publication )

Oncotarget, 2016, 7(30):47387-47402

PubMed: 27329722 ( click the link to review the publication )

Oncotarget, 2016, 7(25):38718-38730

PubMed: 27231850 ( click the link to review the publication )

Oncotarget, 2016,

PubMed: 27014915 ( click the link to review the publication )

Genet Mol Res, 2016, 10.4238/gmr.15027298

PubMed: 27323061 ( click the link to review the publication )

Mutat Res, 2016, 789:1-8

PubMed: 27155559 ( click the link to review the publication )

Cancer Res, 2015, 10.1158/0008-5472.CAN-14-2199

PubMed: 25724678 ( click the link to review the publication )

J Cell Mol Med, 2015, 10.1111/jcmm.12495

PubMed: 25754842 ( click the link to review the publication )

PLoS One, 2015, 10(8):e0134144

PubMed: 26270345 ( click the link to review the publication )

PLoS One, 2015, 10(3):e0122083

PubMed: 25894744 ( click the link to review the publication )

Oncotarget, 2015, 6(15):13476-86

PubMed: 25974963 ( click the link to review the publication )

Purity & Quality Control

Choose Selective RIP kinase Inhibitors

Biological Activity

Description

Features

A powerful tool for characterizing the role of necroptosis with characterized primary target.

Targets

RIP1 ^[1]
(293T cells)

490 nM(EC50)

In vitro

Necrostatin-1 (1-100 μM) inhibits the autophosphorylation of overexpressed and endogenous RIP1.It is found RIP1 is the primary cellular target responsible for the antinecroptosis activity of Necrostatin-1. ^[1] Necrostatin-1 efficiently suppresses necroptotic cell death triggered by an array of stimuli in a variety of cell types. Necrostatin-1, previously identified as small-molecule inhibitor of necroptosis, inhibits RIP kinase-induced necroptosis and inhibits TNF-α-induced necroptosis in jurkat cells with EC50 of 490 nM. ^[2]

Cell Data

Cell Lines	Assay Type	Concentration	Incubation Time	Formulation	Activity Description	PMID
HT-22	M3v6c2N6fG:2b4jpZ4l1gSCDc4PhfS=>	NVXZZ49iOTBizszN	M2fVN\|EzKGh?		NVnvbolweHKxdHXjeJMh[WejaX7zeEBk\WyuIHTlZZRpKGmwZIXj[YQh[nliNdMgcY1wdC:OIHfseZRidWG2ZdMg	MoXPQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOTd5NkC4OlkoRjF5N{[wPFY6RC:jPh?=
Jurkat	NIfCd4RHfW6ldHnvckBCe3OjeR?=	MnnqNlAxyqEQvH2=	M1\Kc\|MxKG2rbh?=		NIDXNGNz\WS3Y3XzxsBP[WWpbHXybYEh\m:5bHXybU1qdmS3Y3XkJJJm[WO2aY\lJI95gWenbjDzdIVkcWW\|IDjSU3MqKGenbnXyZZRqd25?	NI\BXFE9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{MUWzOVAzOCd-MkG1N\|UxOjB:L3G+
Jurkat	M1XIfWN6fG:2b4jpZ4l1gSCDc4PhfS=>	M3TmRlUxNyBzMECvNlAxyqEQvH2=	NVuyVnZqOS9\|IHi=		MnP0doVlfWOnc9MgUoFm\2yncnnhJIZwf2yncnmtbY5lfWOnZDDjfZRwfG:6aXPpeJk>	NWnXRlk5RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkG1N\|UxOjBpPkKxOVM2ODJyPD;hQi=>
SW13	NV:xWZBLS2WubDDWbYFjcWyrdImgRZN{[Xl?	MlK5NVAxKM7:TR?=	NUH6Ro5SOjRiaB?=	NHXQOmRFVVOR	M4W3cIlv[3KnYYPld{Bk\WyudXzhdkB{fXK4aY\hcC=>	M3\jeVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ{MUO2PFE5Lz5{MkGzOlgyQDxxYU6=
8505c	NH;NRWFE\WyuIG\pZYJqdGm2eTDBd5NigQ>?	MVexNFAh\|ryP	MmPqNlQhcA>?	M2SyZWROW09?	NWDDU3hLcW6lcnXhd4V{KGOnbHz1cIFzKHO3co\peoFt	MUm8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOjF\|NkixPEc,OjJzM{[4NVg9N2F-
TPC-1	NX3RXpp[S2WubDDWbYFjcWyrdImgRZN{[Xl?	M1jNPVExOCEQvF2=	M1;qd\|I1KGh?	MVvEUXNQ	MnTabY5kemWjc3XzJINmdGy3bHHyJJN2en[rdnHs	M1\PUVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ{MUO2PFE5Lz5{MkGzOlgyQDxxYU6=
L929sA	MnHsRZBweHSxc3nzJGF{e2G7	MmL5NVAh\|ryP	NEfxS5kyKGh?		MVjhZpJw\2G2ZYOgeIhmKGmwdHXyZYN1cW:wIH;mJINie3Cjc3WtPEB4cXSqIF\BSGQ>	NHrINW49[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{MkO2Nlc3Pyd-MkKzOlI4Pjd:L3G+
L929sA	MXXBdI9xfG:\|aYOgRZN{[Xl?	NWDG[mtZOTBizszN	NHjzSpYyKGh?		NFjESY9z\XOldXXzJINmdGy\|IHX4dJJme3OrbnegVmlRUzIQlFnEJIZzd21iVF7GMYlv\HWlZXSgZZBweHSxc3nz	Mn;WQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjJ\|NkK3OlcoRjJ{M{[yO\|Y4RC:jPh?=
L929sA	NEjjPYRCeG:ydH;zbZMhSXO\|YYm=	NF3rN4wyOCEQvF2=	NVfucXpUOSCq		M4LHO4lvcGmkaYTzJJRp\SCjcH;weI91cWNicnXzdI9ve2VidH:gWG5H	NV22N5BGRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkKzOlI4PjdpPkKyN\|YzPzZ5PD;hQi=>
K562/Adr	M1HGTmZ2dmO2aX;uJGF{e2G7	MoC0OlAh\|ryP	M2HVdlEzKGh?		NXe4UGRXcW6lcnXhd4V{KHSqZTDhZ5Rqfmm2eTDv[kBk[XOyYYPld{wh[2G\|cHHz[UA5KGGwZDC5	MXq8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOjh\|N{[4PUc,OjJ6M{e2PFk9N2F-
K562	MVfGeY5kfGmxbjDBd5NigQ>?	NHLCc4g3OCEQvF2=	NHH2WWQyOiCq		MlnYbY5kemWjc3XzJJRp\SCjY4Tpeol1gSCxZjDjZZNx[XOnczygZ4F{eGG\|ZTC4JIFv\CB7	MnnUQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjJ6M{e2PFkoRjJ{OEO3Olg6RC:jPh?=
HL60/Adr	NHf0T2hHfW6ldHnvckBCe3OjeR?=	MWS2NEDPxE1?	M4L1TlEzKGh?		NUDw[GJycW6lcnXhd4V{KHSqZTDhZ5Rqfmm2eTDv[kBk[XOyYYPld{wh[2G\|cHHz[UA5KGGwZDC5	NWDr[4s4RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkK4N\|c3QDlpPkKyPFM4Pjh7PD;hQi=>
HL60	NHy2eG5HfW6ldHnvckBCe3OjeR?=	MXe2NEDPxE1?	MUOxNkBp		M4DaVYlv[3KnYYPld{B1cGViYXP0bZZqfHlib3[gZ4F{eGG\|ZYOsJINie3Cjc3WgPEBidmRiOR?=	Ml64QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjJ6M{e2PFkoRjJ{OEO3Olg6RC:jPh?=
K562/Adr	MUHGeY5kfGmxbjDBd5NigQ>?	NWHUT41VPjBizszN	MWmxNkBp		MlzOZZVodWWwdIOgeIhmKGOjc4Dhd4UuOyCjY4Tpeol1gQ>?	NHGyOG89[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{MkizO\|Y5QSd-MkK4N\|c3QDl:L3G+
K562	MlrVSpVv[3Srb36gRZN{[Xl?	MlzxOlAh\|ryP	M{Da[lEzKGh?		M1jzOIF2\22nboTzJJRp\SClYYPwZZNmNTNiYXP0bZZqfHl?	NVnobWdTRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkK4N\|c3QDlpPkKyPFM4Pjh7PD;hQi=>
HL60/Adr	NGT4RZRHfW6ldHnvckBCe3OjeR?=	MorxOlAh\|ryP	MYixNkBp		MlfTZZVodWWwdIOgeIhmKGOjc4Dhd4UuOyCjY4Tpeol1gQ>?	NInmWY89[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{MkizO\|Y5QSd-MkK4N\|c3QDl:L3G+
HL60	NIi5c2ZHfW6ldHnvckBCe3OjeR?=	NIHPXJg3OCEQvF2=	M2nVSVEzKGh?		M2\odYF2\22nboTzJJRp\SClYYPwZZNmNTNiYXP0bZZqfHl?	NH;Gb4g9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{MkizO\|Y5QSd-MkK4N\|c3QDl:L3G+
K562/Adr	NGH0PJpCeG:ydH;zbZMhSXO\|YYm=	Ml31OlAh\|ryP	MoG3NVIhcA>?		NUKweody\W6qYX7j[ZMhe2ira3;ubY4ucW6mdXPl[EBieG:ydH;zbZM>	MWO8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOjh\|N{[4PUc,OjJ6M{e2PFk9N2F-
K562	NVHQZYd[SXCxcITvd4l{KEG\|c3H5	NUnROXdpPjBizszN	M2e4cVEzKGh?		NGjlPI5mdmijbnPld{B{cGmtb37pck1qdmS3Y3XkJIFxd3C2b4Ppdy=>	MmTFQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjJ6M{e2PFkoRjJ{OEO3Olg6RC:jPh?=
HL60/Adr	M4XyWmFxd3C2b4Ppd{BCe3OjeR?=	NFK0OXI3OCEQvF2=	M1;KW\|EzKGh?		NWe1UmFP\W6qYX7j[ZMhe2ira3;ubY4ucW6mdXPl[EBieG:ydH;zbZM>	M3yxW\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ{OEO3Olg6Lz5{MkizO\|Y5QTxxYU6=
HL60	MY\BdI9xfG:\|aYOgRZN{[Xl?	NYK0T\|lbPjBizszN	M4fiWlEzKGh?		NWSxZpZ6\W6qYX7j[ZMhe2ira3;ubY4ucW6mdXPl[EBieG:ydH;zbZM>	NIfacnI9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{MkizO\|Y5QSd-MkK4N\|c3QDl:L3G+
SH-EP	NETH[FVCeG:ydH;zbZMhSXO\|YYm=	MUGxNQKBkc7:TdMg	MkHQO\|LjiImqwrC=		M4qzUIlvcGmkaYTzJGlCWCCrbnjpZol1d3JvIHHu[EBN\XijdIXteY1i[i2rbnT1Z4VlKGGyb4D0c5Nqew>?	M{P2T\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ{OEmwN\|IzLz5{Mki5NFMzOjxxYU6=
NIH3T3	NXu3O\|dvTnWwY4Tpc44hSXO\|YYm=	NX7JeIRlOTBxNUCg{txO	NUfDclBXOS9\|IHi=		MmO2ZY1mdGmxcnH0[ZMhXE6IzsGt[JJqfmWwIHPvcZBt\XhiZn;ycYF1cW:w	NX\BN3hLRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkOyOlE3PzdpPkKzNlYyPjd5PD;hQi=>
HT-22	M173UWZ2dmO2aX;uJGF{e2G7	NHzy[GwzPcLizszN	NUPLVJdzOOLCk{OwxsBucW5?	M{XzWWROW09?	NGfoOoNqdmirYnn0d{BGWktiQXP0bZZifGmxbjDpcoR2[2WmIHL5JIdtfXSjbXH0[S=>	NGjDUVU9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{M{OwO\|c2Oid-MkOzNFc4PTJ:L3G+
HT-22	NIHyUWVE\WyuIG\pZYJqdGm2eTDBd5NigQ>?	M2\1[FExyqEQvF2=	MUGxNuKhcA>?	M2rNZmROW09?	M{DlcZBzd3SnY4TzJIFo[Wmwc4Sg[4x2fGGvYYTlMYlv\HWlZXSgZ4VtdCCmZXH0bC=>	MkfGQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjN\|MEe3OVIoRjJ\|M{C3O\|UzRC:jPh?=
KMS-12-BM	NG\MWYhEgXSxdH;4bYNqfHliQYPzZZk>	M1\2U\|kxKML3TR?=	NUOzU49POSCq		MUnicI9kc3NiQlHZJFEyNTdyOEKgbY5lfWOnZDDyZZBq\CClZXzsJJN4\WyuaX7n	Ml7zQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjN3MkexOVQoRjJ\|NUK3NVU1RC:jPh?=
MM.1S	NEnIUmdEgXSxdH;4bYNqfHliQYPzZZk>	MWW5NEDDvU1?	MoD5NUBp		MUficI9kc3NiQlHZJFEyNTdyOEKgbY5lfWOnZDDyZZBq\CClZXzsJJN4\WyuaX7n	Ml\UQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjN3MkexOVQoRjJ\|NUK3NVU1RC:jPh?=
ΔN-Karpas 299	M1HKbWN6fG:2b4jpZ4l1gSCDc4PhfS=>	M{O2W\|IxyqEQvF2=	M1ywUVE3KGh?		NUXrXWN1cW6qaXLpeJMhS0R\|MD3pcoR2[2WmIHPlcIwh\GWjdHi=	Ml7lQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjN3NEW5N\|goRjJ\|NUS1PVM5RC:jPh?=
MEFs	NXXMRWt1TnWwY4Tpc44hSXO\|YYm=	M3zKPFIxyqEQvF2=	MX:xM\|IwPCCq		MXzzeZBxemW\|c3XzJHRPTs7zLXnu[JVk\WRiUlnQT\|EheGixc4Doc5J6dGG2aX;u	MnfRQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjN5Mke1PFEoRjJ\|N{K3OVgyRC:jPh?=
MEFs	NHXXWJFEgXSxdH;4bYNqfHliQYPzZZk>	MXqyM\|YwOjBizszN	NYS0e2M2OThiaB?=		MnPxbY5pcWKrdIOgWG5H\|rFvaX7keYNm\CClZXzsJIRm[XSqIHnuJHJmdEFiS1:gUWVHew>?	NYm2SVYzRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkO3Nlc2QDFpPkKzO\|I4PThzPD;hQi=>
RMS13	M2T3V2NmdGxiVnnhZoltcXS7IFHzd4F6	NUXsV2hJPDEkgJpOwIcwdW{EoB?=	NVv0RWpGOjRiaB?=		MmHRdoV{[3WnczDHXFE2NTB5MD3pcoR2[2WmIHzvd5Mhd2ZiY3XscEB3cWGkaXzpeJk>	M4nMPVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ\|N{S0Nlk3Lz5{M{e0OFI6PjxxYU6=
TE671	NUTGXohxS2WubDDWbYFjcWyrdImgRZN{[Xl?	MkTKOFDjiIoQvHevcYzDqA>?	MXGyOEBp		M1GzWpJme2O3ZYOgS3gyPS1yN{CtbY5lfWOnZDDsc5N{KG:oIHPlcIwhfmmjYnnsbZR6	NHfyT209[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{M{e0OFI6Pid-MkO3OFQzQTZ:L3G+
U87	NF7ET2xHfW6ldHnvckBCe3OjeR?=	NEX2NVMyKG2vb3yvUC=>	NHjFVmcyNjVvMzDo		M3i4UZN2eHC{ZYPz[ZMhfGinIHX4dJJme3Orb36gc4YhWkmSLUGgZ4F2e2WmIHL5JJNpcWuxbnnu	MkC0QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjN6NEC0OFEoRjJ\|OESwOFQyRC:jPh?=
C6	MnTpSpVv[3Srb36gRZN{[Xl?	NGfQVIIyKG2vb3yvUC=>	NITIWHgyNjVvMzDo		NFzSeWF{fXCycnXzd4V{KHSqZTDlfJBz\XO\|aX;uJI9nKFKLUD2xJINifXOnZDDifUB{cGmtb37pci=>	MX28ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOzh2MES0NUc,OjN6NEC0OFE9N2F-
U87	MULDfZRwfG:6aXPpeJkhSXO\|YYm=	M4DTTlEhdW2xbD;M	MWizJIg>		NUHTbVl1[myxY3vzJJNpcWuxbnnuJIlv\HWlZXSgcoVkem:\|aYO=	NE\ZO3U9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{M{i0NFQ1OSd-MkO4OFA1PDF:L3G+
C6	MkXVR5l1d3SxeHnjbZR6KEG\|c3H5	M3HIeVEhdW2xbD;M	MkfFN{Bp		NILwOldjdG:la4Ogd4hqc2:waX6gbY5lfWOnZDDu[YNzd3Orcx?=	NXqyU5QzRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkO4OFA1PDFpPkKzPFQxPDRzPD;hQi=>
U87	MmPwR4VtdCCYaXHibYxqfHliQYPzZZk>	MWGxJI1ud2xxTB?=	Mnm0N{Bp		NEewSGZifHSnboXheIV{KFOqaXvvcolvKGmwZIXj[YQh\2yrb33hJINmdGxiZHXheIg>	M4jwWFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ\|OESwOFQyLz5{M{i0NFQ1OTxxYU6=
C6	Ml;RR4VtdCCYaXHibYxqfHliQYPzZZk>	MmTUNUBudW:uL1y=	NILRRm0{KGh?		MXrheJRmdnWjdHXzJHNpcWuxbnnuJIlv\HWlZXSg[4xqd22jIHPlcIwh\GWjdHi=	MXi8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOzh2MES0NUc,OjN6NEC0OFE9N2F-
L929	M3rxNWZ2dmO2aX;uJGF{e2G7	MYq1xsDPxGdxbXy=	NG\z[5UzPMLiaB?=		M2HxR4Jtd2OtczD6WmFFKGmwZIXj[YQhdmWlcn;weI9{cXNiYX7kJIF2fG:yaHHnfS=>	NEDtWGE9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{M{m0NVc3QSd-MkO5OFE4Pjl:L3G+
L929	NW\v[mhkTnWwY4Tpc44hSXO\|YYm=	MWeyxsDPxGdxbX\|CpC=>	MnLlNlTDqGh?		MlmwdJJwdW:2czDjZZNx[XOnLU[gLJAzOCliYXP0bZZqfHliYX7kJJBzd2Ojc4Dhd4UuPiClbHXheoFo\Q>?	NVHHToxXRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkO5OFE4PjlpPkKzPVQyPzZ7PD;hQi=>
L929	NFLIRVBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NE[xT4UzNzYEoN88[{9udMLi	M1HON\|I1yqCq		NWj0W4JqemW4ZYLz[ZMhfGinIHPlcIwh\3Kxd4ToJIlvcGmkaYTpc44h[W6mIHPlcIwh\GWjdHigbY5lfWOnZDDifUBVVkcQsTDhcI9v\SCjczD3[YxtKGG\|IGTOSu6yyqBtwrD6WmFF	NXXRbG9mRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkO5OFE4PjlpPkKzPVQyPzZ7PD;hQi=>
L929	MWHGeY5kfGmxbjDBd5NigQ>?	NHvzTmczNzYEoN88[{9udMLi	MWOyOOKhcA>?		NVXZTHd5emW4ZYLz[YQhfGinIHH1eI9xcGGpeTDpcoR2[2WmIHL5JHRPTs7zIHHsc45mKGG\|IIflcIwh[XNiVF7G{tHDqCwEoIrWRWQ>	MkTWQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjN7NEG3OlkoRjJ\|OUSxO\|Y6RC:jPh?=
NRK-52E	MkXRR4VtdCCYaXHibYxqfHliQYPzZZk>	M2XZflIxKM7:TR?=	M{PS[\|I1KGh?		MnXpbY5pcWKrdIOgbY5kemWjc3XkJGRzeDFicILveIVqdiCneIDy[ZN{cW:wIHHmeIVzKFSQRj5OtUBUfGmvdXzheIlwdiCjbnSgRXRRKESncHzleIlwdg>?	M2fzSFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ2M{WxPFQ2Lz5{NEO1NVg1PTxxYU6=
NRK-52E	MYfD[YxtKF[rYXLpcIl1gSCDc4PhfS=>	MVeyNEDPxE1?	NV24O\|FvOjRiaB?=		NEjVWZpqdmO{ZXHz[ZMh[2WubDD2bYFjcWyrdImgZYZ1\XJiVF7GMe6yKFO2aX31cIF1cW:wIHHu[EBCXFBiRHXwcIV1cW:w	NHW0fYg9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NEO1NVg1PSd-MkSzOVE5PDV:L3G+
NRK-52E	NWfRUXR4S2WubDDWbYFjcWyrdImgRZN{[Xl?	NF\YVXczOCEQvF2=	NEfPWFczPCCq		NXHISGg1eHKxdHXjeJMh[2WubIOg[pJwdSClZXzsJIRm[XSqIHPheZNm\CCkeTDpd4Np\W2rYTDpcop2enl?	M3n0eVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ2M{WxPFQ2Lz5{NEO1NVg1PTxxYU6=
AGS	MXLD[YxtKF[rYXLpcIl1gSCDc4PhfS=>	NXm0e5ZCPjEkgJpOwI0>	NY\qNo1FOeLCiXi=		MkfUdJJmfmWwdIOgd4hqc2:waX6tbY5lfWOnZDDj[YxtKGSnYYTo	MVG8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPDR4M{G5PUc,OjR2NkOxPVk9N2F-
L-540	MXnD[YxtKF[rYXLpcIl1gSCDc4PhfS=>	NFi0NW43OOLCid88cS=>	Mo\uNgKBkWh?		NF;NSYFz\WS3Y3XzJJRp\SCJaY\pco9{fGG2L2PvdoFn\W6rYj3pcoR2[2WmIHPlcIwh\GWjdHi=	MXq8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPDV4MUWxPUc,OjR3NkG1NVk9N2F-
L-540	MXrGeY5kfGmxbjDBd5NigQ>?	NHvyNlQ3OOLCid88cS=>	MV2x5qCKcA>?		M4rRNZBz\X[nboTzJJRp\SCvaYTvZ4hwdmS{aXHsJI1mdWK{YX7lJIRmeG:uYYLpfoF1cW:w	M2fQOVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ2NU[xOVE6Lz5{NEW2NVUyQTxxYU6=
L-540	MmPrSpVv[3Srb36gRZN{[Xl?	MlHnOlDjiIoQvH2=	NXG5bmVWOeLCiXi=		MmrhdJJmfmWwdIOgeIhmKGenbnXyZZRqd25ib3[gVm9U	NHHPd2k9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NEW2NVUyQSd-MkS1OlE2OTl:L3G+
SK-Hep1	MnPzSpVv[3Srb36gRZN{[Xl?	MknPOlDjiIoQvF5CpC=>	NIPvdIkyQOLCiXi=		MUTicI9kc3QEoN8yMYxieGGlaH;u[U1u\WSrYYTl[EBRSVJiYXPjeY12dGG2aX;uJIFv\CCDSV[geJJidnOub3PheIlwdiC2bzD0bIUh[3m2b4PvcOKh	NUj5d3Z{RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkS4N\|I3ODJpPkK0PFMzPjB{PD;hQi=>
SK-Hep1	NXzDbZBlTnWwY4Tpc44hSXO\|YYm=	NE\HXHA3OOLCid88UeKh	M4nWcVE56oDLaB?=		MkfJbY5pcWKrdIOg{tIuVGGyYXPoc45mNWmwZIXj[YQhdGWja3Hn[UBw\iCKTVfCMVHDqA>?	NXvNfXUzRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkS4N\|I3ODJpPkK0PFMzPjB{PD;hQi=>
SK-Hep1	M2PkOWZ2dmO2aX;uJGF{e2G7	M3rvZ\|Yx6oDLzszNxsA>	M1XxdFE56oDLaB?=		NFHHcXFjdG:la4RCpO6zNWyjcHHjbI9v\S2rbnT1Z4VlKG2xcoDoc4xw\2mlYXygZ4hidmenLDDj[YxtKGSnYYToJIFv\CCSSTD1dJRic2V?	MVm8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPDh\|Mk[wNkc,OjR6M{K2NFI9N2F-
OHC	MWPGeY5kfGmxbjDBd5NigQ>?	MUmzNFDjiIoQvF2=		M1X3e2ROW09?	MVnpcoNz\WG\|ZYOgeIhmKG63bXLldkBw\iCjcH;weI91cWNiT1jDd{B4cXSqb4X0JIFtfGW{aX7nJJRp\SCuZY\lcJMhd2ZiQ1O4JIFnfGW{IH7vbZNmKGW6cH;zeZJm	NXq1XJBtRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkS4O\|Q4OzRpPkK0PFc1PzN2PD;hQi=>
OHC	MWXGeY5kfGmxbjDBd5NigQ>?	MXGzNFDjiIoQvF2=		NYTCSHBiTE2VTx?=	MXzkbY1qdmm\|aHXzJI5wcXOnLXnu[JVk\WRiQV3QT{Bi[3SrdnH0bY9v	M1;UZ\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ2OEe0O\|M1Lz5{NEi3OFc{PDxxYU6=
OHC	MmjESpVv[3Srb36gRZN{[Xl?	NUe5OWpnOzBy4pEJ{txO		MX7EUXNQ	MVzy[ZN2dHS\|IHnuJIEhemWmdXP0bY9vKG:oIH7vbZNmNWmwZIXj[YQhWkmSMTDhcoQhWkmSMzDpcY12dm:obIXvdoV{[2WwY3W=	NE[4fFg9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NEi3OFc{PCd-MkS4O\|Q4OzR:L3G+
OHC	MUPGeY5kfGmxbjDBd5NigQ>?	MVWzNFDjiIoQvF2=		M3\Gc2ROW09?	M4\6eYRm[3KnYYPld{Bvd2m\|ZT3pcoR2[2WmIIP3c4xt\W5iboXjcIVqyqB?	NGDkV2w9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NEi3OFc{PCd-MkS4O\|Q4OzR:L3G+
OHC	NYX1WGlnTnWwY4Tpc44hSXO\|YYm=	NH;FbpI{ODEkgJpOwG0>		NWXxV4VoTE2VTx?=	NIC3XlBqdmO{ZXHz[ZMhdm:rc3WtbY5lfWOnZDDjc45l\W6\|ZXSgcpVkdGWr	NIPkcoI9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NEi3OFc{PCd-MkS4O\|Q4OzR:L3G+
Huh7	MYXD[YxtKF[rYXLpcIl1gSCDc4PhfS=>	M2XQPVUxKML3TR?=	NUnsd49EOjRxNEigbC=>	M1zaVmROW09?	MUfwdoV3\W62czDj[YxtKGSnYYToJI9nKHKDZFjDWkBkdy2rbn\lZ5Rm\CCKdXi3JINmdGy\|	M1nTOlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ2OUezNlQxLz5{NEm3N\|I1ODxxYU6=
L929	NYPaWFR3S2WubDDWbYFjcWyrdImgRZN{[Xl?	MoGxN\|DDqM7:TR?=	NYPJdWdSOcLiaB?=		NVfRT\|dqcW6qaXLpeJMhXE6ILd8xMYlv\HWlZXSgZ4xm[X[jZ3Wgc4YhXG:ybzDJ	NX7GT49vRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkWwPVU4PDJpPkK1NFk2PzR{PD;hQi=>
L929	Ml\wR4VtdCCYaXHibYxqfHliQYPzZZk>	MV:zNOKh\|ryP	MX6xxsBp		MkTIbY5pcWKrdIOgWG5HNc7zLXnu[JVk\WRibH;zd{Bw\iClZXzsJJZq[WKrbHn0fS=>	M1jyNVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ3MEm1O\|QzLz5{NUC5OVc1OjxxYU6=
L929-A	NH3iVVJHfW6ldHnvckBCe3OjeR?=	NUXxV214PTEEoN88UeKh	NYexO4hoOTJiaB?=		Mlv3bY5pcWKrdIOgeIhmKFSQRt8xMYlv\HWlZXSgcI9{eyCxZjDtbZRw[2ixbnTybYFtKG2nbXLyZY5mKHCncn3lZYJqdGm2eR?=	M4LJZVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ3M{m4OVQxLz5{NUO5PFU1ODxxYU6=
L929	NYLlU41TTnWwY4Tpc44hSXO\|YYm=	NXn3eodHPTEEoN88UeKh	M2qzZVEzKGh?		M4L0NYlvcGmkaYTzJHRPTs7zLXnu[JVk\WRiQnnkJINt\WG4YXfl	Mn\HQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjV\|OUi1OFAoRjJ3M{m4OVQxRC:jPh?=
L929-N	NV31RVN3TnWwY4Tpc44hSXO\|YYm=	MYG1NOKh\|ryPwrC=	M1PrN\|EzKGh?		NE\QV3VjdG:la4OgeIhmKGOuZXH2ZYdmKG:oIFPhd5Bie2VvMzDhcoQhWEGUUB?=	M17qPVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ3M{m4OVQxLz5{NUO5PFU1ODxxYU6=
L929-A	MU\GeY5kfGmxbjDBd5NigQ>?	MoLSOVDDqM7:TdMg	M2X3[\|EzKGh?		NXzmZVZp[myxY3vzJJRp\SClbHXheoFo\SCxZjDDZZNx[XOnLUOgZY5lKFCDUmC=	NWrWcGJpRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkWzPVg2PDBpPkK1N\|k5PTRyPD;hQi=>
L929-N	M3zPcmNmdGxiVnnhZoltcXS7IFHzd4F6	MmrsOVDDqM7:TdMg	NE\3bGUzPCCq		Mnj3Zoxw[2u\|IGTOSu6yNWmwZIXj[YQh[2WubDDk[YF1cA>?	NXfndHpxRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkWzPVg2PDBpPkK1N\|k5PTRyPD;hQi=>
L929-A	MVnD[YxtKF[rYXLpcIl1gSCDc4PhfS=>	NIfYPXA2OMLizszNxsA>	MlK3NlQhcA>?		M{PqR4Jtd2OtczDUUmbPuS2rbnT1Z4VlKGOnbHyg[IVifGh?	MniyQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjV\|OUi1OFAoRjJ3M{m4OVQxRC:jPh?=
KMS-12-PE	M1nFR2NmdGxiVnnhZoltcXS7IFHzd4F6	NUP3enp5PjBizszN	MWK1JIg>		MXvpcohq[mm2czDTTGsucW6mdXPl[EBk\WyuIHTlZZRp	MXW8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPTV\|MEC5PEc,OjV3M{CwPVg9N2F-
SGC-7901	M3TxfWNmdGxiVnnhZoltcXS7IFHzd4F6	MWCzNOKh\|ryP	NF\GTGcyyqCq		MWXzeZBxemW\|c3XzJI95[WyrcHzheIlvNW2nZHnheIVlKGOnbHyg[IVifGh?	NVKzemJtRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkW3OlcxPzZpPkK1O\|Y4ODd4PD;hQi=>
BxPC-3	NFrIWpBHfW6ldHnvckBCe3OjeR?=	MWGyNEDPxE1?	MYCyOEBp		NYrnVYRK\GWlcnXhd4V{KHSqZTDlZZJtgSCwZXPyc5Rq[yClZXzsdy=>	NXPQXWliRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMk[wNFA3ODdpPkK2NFAxPjB5PD;hQi=>
MiaPaCa-2	NV\HdWlxTnWwY4Tpc44hSXO\|YYm=	NH3YW\|QzOCEQvF2=	MnnvNlQhcA>?		MYjk[YNz\WG\|ZYOgeIhmKGWjcnz5JI5m[3KxdHnjJINmdGy\|	M3fXRlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ4MECwOlA4Lz5{NkCwNFYxPzxxYU6=
NCI-H28	NUTVeI5wS2WubDDWbYFjcWyrdImgRZN{[Xl?	NV:4OGg6OTEEoN88US=>	NU\v[HpbOjUEoHi=		NXzkT3lbeHKndnXueJMhTEGSRT3pcoR2[2WmIILl[JVkfGmxbjDv[kBPS0lvSEK4JINmdGxidnnhZoltcXS7wrC=	MkPzQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjZyMESxN\|goRjJ4MEC0NVM5RC:jPh?=
BMDM	MnK5SpVv[3Srb36gRZN{[Xl?	NVvMSo5zOTEEoN88US=>	MkS2N\|DDqG2rbh?=		Mof4dJJwfGWldIOgZ4VtdHNiZoLvcUBVSUuLLXnu[JVk\WRiTFTIJJJmdGWjc3W=	NFniNYc9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NkO4NVYxOSd-Mk[zPFE3ODF:L3G+
MEFs	MVHD[YxtKF[rYXLpcIl1gSCDc4PhfS=>	NFfvTWwyOOLCid88US=>	NXLEXJhxPDhiaB?=	M1XhemROW09?	Moj3bY5pcWKrdIOgfnZCTC2ycn;tc5Rm\CCmZXH0bEBw\iCFTl;UN{1l\XCuZYTl[EBOTU[\|	NF\zXXM9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NkSzO\|c5QSd-Mk[0N\|c4QDl:L3G+
A549	MnjRR4VtdCCYaXHibYxqfHliQYPzZZk>	MnPvOVDDqM7:TR?=	NFjxeW4zPMLiaB?=		NWTHSIhLcW6qaXLpeJMhVU2VLXnu[JVk\WRiY3XscEBl\WG2aB?=	NVPnfVhURGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMk[0O\|I4OjNpPkK2OFczPzJ\|PD;hQi=>
Jurkat T	MmC1UoVkem:ydH;zbZMh[XO\|YYm=				NHXxNHZKdmirYnn0bY9vKG:oIGTOSk1idHCqYT3pcoR2[2WmIH7lZ5JweHSxc3nzJIlvKE[DRFSt[IVncWOrZX70JIh2dWGwIFr1dotifCCWIHPlcIx{NCCHQ{WwJF0hOC5yNTFOwG0v	M2jQWlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzF6NE[3NFk1Lz5zOES2O\|A6PDxxYU6=
Jurkat	M4TxWWZ2dmO2aX;uJIF{e2G7				NXjyeZNJUW6qaXLpeIlwdiCxZjDlcoRw\2Wwb4XzJHJKWDFiYYX0c5Bpd3OyaH;yfYxifGmxbjDpckBpfW2jbjDKeZJs[XRiY3XscJMtKEWFNUCgQUAxNjF6MjFOwG0v	NVvIUmJoRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMUi0NFg4OTNpPkG4OFA5PzF\|PD;hQi=>
Sf9	MWDGeY5kfGmxbjDhd5NigQ>?		MmjPN\|AhdWmwcx?=		MV7Jcohq[mm2aX;uJI9nKHKnY3;tZolv[W62IHj1cYFvKEeVVD3meZNm\CCUSWDLNUApOSC2bzC0PVchemW\|aXT1[ZMqKGW6cILld5Nm\CCrbjDiZYN2dG:4aYL1d{Bqdm[nY4Tl[EBqdnOnY4SgV4Y6KGOnbHzzJIlvKHC{ZYPlcoNmKG:oIEOyVE1o[W2vYT3BWHAh[W[2ZYKgN\|AhdWmwczDifUBifXSxcnHkbY9oemGvLXLhd4VlKFenc4Tldo4h[myxdDDt[ZRpd2RuIFnDOVAhRSByLkG4NkDPxE1w	NH:3TZc9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{OEK4NFI3OSd-MkiyPFAzPjF:L3G+
Jurkat T	M{Lpe25m[3KxcITvd4l{KGG\|c3H5				NHzGS5dG\m[nY4TpeoUh[2:wY3XueJJifGmxbjDy[ZF2cXKnZDDmc5IhcW6qaXLpeIlwdiCxZjDu[YNzd3C2b4Ppd{BqdiCIQVTEJIRm\mmlaXXueEBLfXKtYYSgWEBk\WyuczD0doVifGWmIIfpeIghXE6ILXHsdIhiNCCHQ{WwJF0hOC52OTFOwG0v	NG\PXno9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9zNkG1N\|g1OCd-MU[xOVM5PDB:L3G+
Jurkat	M2ftem5m[3KxcITvd4l{KGG\|c3H5				NFe2TYNKdmirYnn0bY9vKG:oIHPlcIx2dGG{IH7lZ5JweHSxc3nzJIlvKFSQRnHsdIhiKHS{ZXH0[YQhTkGGRDDk[YZq[2mnboSgbJVu[W5iSoXyb4F1KGOnbHzzMEBGSzVyIE2gNE41QSEQvF2u	NFjNUog9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9zOESwPFcyOyd-MUi0NFg4OTN:L3G+
Jurkat T	MULO[YNzd3C2b4Ppd{Bie3OjeR?=	MnnWN\|AhfU1?	NWe3dJNJOjRiaILz		MXXJcohq[mm2aX;uJI9nKG6nY4LvdJRwe2m\|IHnuJHRPTi2jbIDoZU1qdmS3Y3XkJIh2dWGwIFr1dotifCCWIHPlcIx{KGG\|c3Xzd4VlKGG\|IHPlcIwhfmmjYnnsbZR6KGG2IEOwJJVOKGGodHXyJFI1KGi{cx?=	M1nCVFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzF6NE[3NFk1Lz5zOES2O\|A6PDxxYU6=
L929	Ml61UoVkem:ydH;zbZMh[XO\|YYm=	Mn6xN\|AhfU1?	NVrMWXdjOjRiaILz		NFXv[3RKdmirYnn0bY9vKG:oIH7lZ5JweHSxc3nzJIlvKHqYQVStbY5lfWOnZDDtc5V{\SCOOUK5JINmdGy\|IHHzd4V{e2WmIHHzJINmdGxidnnhZoltcXS7IHH0JFMxKHWPIHHmeIVzKDJ2IHjydy=>	MmHCQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOTh2NkewPVQoRjF6NE[3NFk1RC:jPh?=
L929	NVnTcmVKVmWlcn;weI9{cXNiYYPzZZk>	NXG0dnRTOzBidV2=	M{\QZVI1KGi{cx?=		M3;x[2lvcGmkaYTpc44hd2ZibnXjdo9xfG:\|aYOgbY4hXE6ILXHsdIhiNWmwZIXj[YQhdW:3c3WgUFkzQSClZXzsd{Bie3Onc4Pl[EBieyClZXzsJJZq[WKrbHn0fUBifCB\|MDD1UUBi\nSncjCyOEBpenN?	MYe8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8yQDR4N{C5OEc,OTh2NkewPVQ9N2F-
3T3	MX7D[YxtKGSnYYToJIF{e2G7		MX:yOEBpenN?		NXS0V5NlUW6qaXLpeIlwdiCxZjDk[YF1cCC{ZXPldJRweiC\|aXfuZYxqdmdibXXkbYF1\WRibnXjdo91cWNiY3XscEBl\WG2aDDpckBud3W\|ZTCzWFMh[2WubIOgZZN{\XO\|ZXSgZZMh[2WubDD2bYFjcWyrdImgZYZ1\XJiMkSgbJJ{KGK7IFHUVEBj[XOnZDD2bYFjcWyrdImgZZN{[XliaX6gdJJme2WwY3Wgc4YhXE6IYXzwbIEh[W6mIIrWRWQv\m2t	M2XLSVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzF4NEC4NFA5Lz5zNkSwPFAxQDxxYU6=
3T3	MUjD[YxtKGSnYYToJIF{e2G7		MnvyNlQhcHK\|		NFX4U2tKdmirYnn0bY9vKG:oIHTlZZRpKHKnY3XweI9zKHOrZ37hcIlv\yCvZXTpZZRm\CCwZXPyc5Rq[yClZXzsJIRm[XSqIHnuJI1wfXOnIEPUN{Bk\WyuczDhd5Nme3OnZDDhd{Bk\WyuII\pZYJqdGm2eTDh[pRmeiB{NDDodpMh[nliQWTQJIJie2WmII\pZYJqdGm2eTDhd5NigSCrbjDwdoV{\W6lZTDv[kBH[XOOIHHu[EB7XkGGLn\tby=>	NFOzSok9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9zNkSwPFAxQCd-MU[0NFgxODh:L3G+
MEF	M4fZNGNmdGxiZHXheIgh[XO\|YYm=		MWmxOkBpenN?		NFvEUHhKdmirYnn0bY9vKG:oIHTlZZRpKHKnY3XweI9zKHOrZ37hcIlv\yCvZXTpZZRm\CCwZXPyc5Rq[yClZXzsJIRm[XSqIHnuJHNXPDBidILhcpNnd3KvZXSgcY92e2ViTVXGJINmdGy\|IHHzd4V{e2WmIHHzJINmdGxidnnhZoltcXS7IHHmeIVzKDF4IHjyd{BjgSCDVGCgZoF{\WRidnnhZoltcXS7IHHzd4F6KGmwIIDy[ZNmdmOnIH;mJHRPTmGucHjhMEBEUFhiYX7kJJpXSURwZn3r	MXq8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8yPjRyOECwPEc,OTZ2MEiwNFg9N2F-
IEC18	NH3UUFNE\WyuIHTlZZRpKGG\|c3H5				Ml3XTY5pcWKrdHnvckBw\iCmZXH0bEBz\WOncITvdkB{cWewYXzpcochdWWmaXH0[YQhdmWlcn;0bYMh[2WubDDk[YF1cCCrbjDyZZQhUUWFMUigZ4VtdHNiYYPz[ZN{\WRiYYOgZ4VtdCC4aXHibYxqfHliaX6gdJJme2WwY3Wgc4YhXE6IYXzwbIEh[W6mIIrWRWQv\m2t	M3TQWFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzF4NEC4NFA5Lz5zNkSwPFAxQDxxYU6=
HL60	M365cWNmdGxiZHXheIgh[XO\|YYm=				NWXFTJRVUW6qaXLpeIlwdiCxZjDk[YF1cCC{ZXPldJRweiC\|aXfuZYxqdmdibXXkbYF1\WRibnXjdo91cWNiY3XscEBl\WG2aDDpckBpfW2jbjDIUFYxKGOnbHzzJIF{e2W\|c3XkJIF{KGOnbHygeoli[mmuaYT5JIlvKHC{ZYPlcoNmKG:oIGTOSoFteGijIHHu[EB7XkGGLn\tby=>	NX24UVVQRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMU[0NFgxODhpPkG2OFA5ODB6PD;hQi=>
L929	MnzwR4VtdCCmZXH0bEBie3OjeR?=		NFXWdWYzPCCqcoO=		Mn\xTY5pcWKrdHnvckBw\iCmZXH0bEBz\WOncITvdkB{cWewYXzpcochdWWmaXH0[YQhdmWlcn;0bYMh[2WubDDk[YF1cCCrbjDtc5V{\SCOOUK5JINmdGy\|IHHzd4V{e2WmIHHzJINmdGxidnnhZoltcXS7IHHmeIVzKDJ2IHjyd{BjgSCDVGCgZoF{\WRidnnhZoltcXS7IHHzd4F6KGmwIIDy[ZNmdmOnIH;mJHRPTmGucHjh	MV:8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8yPjRyOECwPEc,OTZ2MEiwNFg9N2F-
Jurkat	MlvUUoVkem:\|aYOgZZN{[Xl?				Mon1TY5pcWKrdHnvckBw\iCwZXPyc5NqeyCrbjDoeY1idiCMdYLrZZQh[2WubIOgZZN{\XO\|ZXSgZZMhdnWlbHXhdkBkd26mZX7zZZRqd25iYomgZpJq\2i2IH\p[YxlKG2rY4Lvd4NweHliaX6gdJJme2WwY3Wgc4YhTmG\|TDygR2hZKGGwZDD6WmFFNW[vax?=	MoG4QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOTZ2MEiwNFgoRjF4NEC4NFA5RC:jPh?=
Jurkat	NXr4TJV4VmWlcn;zbZMh[XO\|YYm=				MmW0TY5pcWKrdHnvckBw\iCwZXPyc5NqeyCrbjDoeY1idiCMdYLrZZQh[2WubIOgZZN{\XO\|ZXSgZZMhd3KpYX7lcIxmKHO5ZXzsbY5oKGK7IHLybYdpfCCoaXXs[EBucWO{b4Pjc5B6KGmwIIDy[ZNmdmOnIH;mJGZie0xuIFPIXEBidmRiem\BSE1ndWt?	MkfhQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOTZ2MEiwNFgoRjF4NEC4NFA5RC:jPh?=
Jurkat	MnHuUoVkem:\|aYOgZZN{[Xl?				NGTpcJNKdmirYnn0bY9vKG:oIH7lZ5Jwe2m\|IHnuJIh2dWGwIFr1dotifCClZXzsd{Bie3Onc4Pl[EBieyCnYYLsfUBtd3O\|IH;mJJBt[XOvYTDt[Y1jemGwZTDpcpRm\3KrdImgZpkh[nKrZ3j0JIZq\WymIH3pZ5Jwe2OxcImgbY4heHKnc3XuZ4Uhd2ZiRnHzUEwhS0i[IHHu[EB7XkGGLX\tby=>	NHLFfG49[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9zNkSwPFAxQCd-MU[0NFgxODh:L3G+
Jurkat	NWDQXHp7VmWlcn;zbZMh[XO\|YYm=				NEPXfWRKdmirYnn0bY9vKG:oIH7lZ5Jwe2m\|IHnuJIh2dWGwIFr1dotifCClZXzsd{Bie3Onc4Pl[EBieyCjcIDlZZJidmOnIH;mJJRz[W6\|bIXj[Y51KGO7dH;zc4whcW5icILld4Vv[2Vib3[gSoF{VCxiQ1jYJIFv\CC8VlHEMYZucw>?	MkTIQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOTZ2MEiwNFgoRjF4NEC4NFA5RC:jPh?=
Jurkat	NI\sOXhP\WO{b4Ppd{Bie3OjeR?=				MljNTY5pcWKrdHnvckBw\iCwZXPyc5NqeyCrbjDoeY1idiCMdYLrZZQh[2WubIOg[IVncWOrZX70JIlvKE[DRFSgZZN{\XO\|ZXSgZZMhcW6qaXLpeIlwdiCxZjDueYNt\WG{IHPvcoRmdnOjdHnvckBjgSCkcnnnbJQh\mmnbHSgcYlkem:\|Y3;wfUBqdiCycnXz[Y5k\SCxZjDUUmZidHCqYR?=	M{DRVFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzF4NEC4NFA5Lz5zNkSwPFAxQDxxYU6=
Jurkat	MW\O[YNzd3OrczDhd5NigQ>?				M4DmWmlvcGmkaYTpc44hd2ZibnXjdo9{cXNiaX6gbJVu[W5iSoXyb4F1KGOnbHzzJIRm\mmlaXXueEBqdiCIQVTEJIF{e2W\|c3XkJIF{KGmwaHnibZRqd25ib3[gc5Jo[W6nbHzlJJN4\WyuaX7nJIJ6KGK{aXfoeEBncWWuZDDtbYNzd3Olb4D5JIlvKHC{ZYPlcoNmKG:oIGTOSoFteGij	MkPpQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOTZ2MEiwNFgoRjF4NEC4NFA5RC:jPh?=
Jurkat	NFPkfG5P\WO{b4Ppd{Bie3OjeR?=				NGTvUoNKdmirYnn0bY9vKG:oIH7lZ5Jwe2m\|IHnuJIh2dWGwIFr1dotifCClZXzsd{Bl\W[rY3nlcpQhcW5iRlHESEBie3Onc4Pl[EBieyCrbnjpZol1cW:wIH;mJIViemy7IHzvd5Mhd2ZicHzhd41iKG2nbXLyZY5mKGmwdHXndol1gSCkeTDidolocHRiZnnlcIQhdWmlcn;zZ49xgSCrbjDwdoV{\W6lZTDv[kBVVk[jbIDoZS=>	NXntUndTRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMU[0NFgxODhpPkG2OFA5ODB6PD;hQi=>
Jurkat	MYXO[YNzd3OrczDhd5NigQ>?				NUXhU3k6UW6qaXLpeIlwdiCxZjDu[YNzd3OrczDpckBpfW2jbjDKeZJs[XRiY3XscJMh\GWoaXPp[Y51KGmwIF\BSGQh[XO\|ZYPz[YQh[XNiaX7obYJqfGmxbjDv[kBieHCnYYLhcoNmKG:oIITyZY5{dHWlZX70JIN6fG:\|b3ygbY4heHKnc3XuZ4Uhd2ZiVF7GZYxxcGF?	MlrVQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOTZ2MEiwNFgoRjF4NEC4NFA5RC:jPh?=
U937	M4PycmNmdGxiZHXheIgh[XO\|YYm=		NVraWWVFPDhiaILz		MVnJcohq[mm2aX;uJI9nKGSnYYToJJJm[2WydH;yJJNq\26jbHnu[{Bu\WSrYYTl[EBv\WO{b4D0c5Rq[yClZXzsJIRm[XSqIHnuJIh2dWGwIGW5N\|ch[2WubIOgZZN{\XO\|ZXSgZZMh[2WubDD2bYFjcWyrdImgZYZ1\XJiNEigbJJ{KGK7IFHUVEBj[XOnZDD2bYFjcWyrdImgZZN{[XliaX6gdJJme2WwY3Wgc4YhXE6IYXzwbIEh[W6mIIrWRWQu\m2t	NYDYTYZmRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMU[0NFgxODhpPkG2OFA5ODB6PD;hQi=>
3T3	MXnD[YxtKGSnYYToJIF{e2G7		MmDWNlQhcHK\|		M1nyOmlvcGmkaYTpc44hd2ZiZHXheIghemWlZYD0c5Ihe2mpbnHsbY5oKG2nZHnheIVlKG6nY4LvdJRwfGmlIHPlcIwh\GWjdHigbY4hdW:3c3WgN3Q{KGOnbHzzJIF{e2W\|c3XkJIF{KGOnbHygeoli[mmuaYT5JIFnfGW{IEK0JIhzeyCkeTDBWHAh[mG\|ZXSgeoli[mmuaYT5JIF{e2G7IHnuJJBz\XOnbnPlJI9nKFSQRnHsdIhiKGGwZDD6WmFFNW[vax?=	NYXXcJdVRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMU[0NFgxODhpPkG2OFA5ODB6PD;hQi=>
Jurkat	Mm\GR4VtdCCmZXH0bEBie3OjeR?=		MV:yOEBpenN?		MlXzTY5pcWKrdHnvckBw\iCmZXH0bEBz\WOncITvdkB{cWewYXzpcochdWWmaXH0[YQhdmWlcn;weI91cWNiY3XscEBl\WG2aDDpckBpfW2jbjDKeZJs[XRiY3XscJMh\GWoaXPp[Y51KGmwIF\BSGQh[XO\|ZYPz[YQh[XNiZHXjdoVie2WmIHzleoVteyCxZjDQSU1kd26sdXfheIVlKEyFMz3JTUAp[XW2b4DoZYd6KG2jcnvldkkh[W[2ZYKgNlQhcHK\|IHL5JHdme3Sncn6gZoxwfCCvZYToc4QhcW5icILld4Vv[2Vib3[gWG5H[WyyaHG=	NXvmbHg3RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMU[0NFgxODhpPkG2OFA5ODB6PD;hQi=>
L929	MlXtR4VtdCCmZXH0bEBie3OjeR?=		NVn3W2tVOjRiaILz		NXm4PZVRUW6qaXLpeIlwdiCxZjDk[YF1cCC{ZXPldJRweiC\|aXfuZYxqdmdibXXkbYF1\WRibnXjdo9xfG:2aXOgZ4VtdCCmZXH0bEBqdiCvb4Xz[UBNQTJ7IHPlcIx{KGG\|c3Xzd4VlKGG\|IHTlZ5Jm[XOnZDDs[ZZmdHNib3[gVGUu[2:waoXnZZRm\CCjdYTvdIhi\3libXHyb4VzKEyFMz3JTUBi\nSncjCyOEBpenNiYomgW4V{fGW{bjDicI91KG2ndHjv[EBqdiCycnXz[Y5k\SCxZjDUUmZidHCqYR?=	NV\NT\|J2RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMU[0NFgxODhpPkG2OFA5ODB6PD;hQi=>
3T3	MnrSR4VtdCCmZXH0bEBie3OjeR?=		MYOyOEBpenN?		M4\K[2lvcGmkaYTpc44hd2ZiZHXheIghemWlZYD0c5Ihe2mpbnHsbY5oKG2nZHnheIVlKG6nY4LvdJRwfGmlIHPlcIwh\GWjdHigbY4hdW:3c3WgN3Q{KGOnbHzzJIF{e2W\|c3XkJIF{KGSnY4LlZZNm\CCuZY\lcJMhd2ZiUFWtZ49vcnWpYYTl[EBifXSxcHjh[5khdWG{a3XyJGxEOy2LSTDh[pRmeiB{NDDodpMh[nliV3XzeIVzdiCkbH;0JI1mfGixZDDpckBxemW\|ZX7j[UBw\iCWTl\hcJBp[SCjbnSgfnZCTC2obXu=	M3rYXVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzF4NEC4NFA5Lz5zNkSwPFAxQDxxYU6=
3T3	MnHER4VtdCCmZXH0bEBie3OjeR?=		MmLLNlQhcHK\|		MYjJcohq[mm2aX;uJI9nKGSnYYToJJJm[2WydH;yJJNq\26jbHnu[{Bu\WSrYYTl[EBv\WO{b4D0c5Rq[yClZXzsJIRm[XSqIHnuJI1wfXOnIEPUN{Bk\WyuczDhd5Nme3OnZDDhd{Bl\WO{ZXHz[YQhdGW4ZXzzJI9nKFCHLXPvcop2\2G2ZXSgZZV1d3CqYXf5JI1iemuncjDMR\|MuUUliYX\0[ZIhOjRiaILzJIJ6KFenc4Tldo4h[myxdDDt[ZRpd2RiaX6gdJJme2WwY3Wgc4YhTmG\|TDDhcoQhgl[DRD3mcYs>	MUe8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8yPjRyOECwPEc,OTZ2MEiwNFg9N2F-
3T3	MVjD[YxtKGSnYYToJIF{e2G7		MXGyOEBpenN?		NH[0TWlKdmirYnn0bY9vKG:oIHTlZZRpKHKnY3XweI9zKHOrZ37hcIlv\yCvZXTpZZRm\CCwZXPyc5B1d3SrYzDj[YxtKGSnYYToJIlvKG2xdYPlJFNVOyClZXzsd{Bie3Onc4Pl[EBieyCmZXPy[YF{\WRibHX2[Yx{KG:oIGDFMYNwdmq3Z3H0[YQh[XW2b4DoZYd6KG2jcnvldkBNSzNvSVmgZYZ1\XJiMkSgbJJ{KGK7IGfld5Rmem5iYnzveEBu\XSqb3SgbY4heHKnc3XuZ4Uhd2ZicnHwZY16[2mw	M1HNXlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzF4NEC4NFA5Lz5zNkSwPFAxQDxxYU6=
Jurkat	MlTJR4VtdCCmZXH0bEBie3OjeR?=		MlnCOFghcHK\|		MYrJcohq[mm2aX;uJI9nKGSnYYToJJJm[2WydH;yJJNq\26jbHnu[{Bu\WSrYYTl[EBv\WO{b4D0c5Rq[yClZXzsJIRm[XSqIHnuJIh2dWGwIFr1dotifCClZXzsd{Bl\W[rY3nlcpQhcW5iRlHESEBidmRiZYjwdoV{e2mwZzDGT2JROTJvYnHz[YQh\GmvZYLpfoF1cW:wIHTvcYFqdiCjc4Pld5Nm\CCjczDj[YxtKH[rYXLpcIl1gSCjZoTldkA1QCCqcoOgZpkhTkGFUzDpckBxemW\|ZX7j[UBw\iCDUEG1NVAtKHqYQVSt[o1s	Mmj3QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOTZ2MEiwNFgoRjF4NEC4NFA5RC:jPh?=
Jurkat	MU\D[YxtKGSnYYToJIF{e2G7		NH74V5g1QCCqcoO=		NV3sXIdGUW6qaXLpeIlwdiCxZjDk[YF1cCC{ZXPldJRweiC\|aXfuZYxqdmdibXXkbYF1\WRibnXjdo9xfG:2aXOgZ4VtdCCmZXH0bEBqdiCqdX3hckBLfXKtYYSgZ4VtdHNiZHXmbYNq\W62IHnuJGZCTERiYX7kJIV5eHKnc4PpcochWkmSIHvpcoF{\SCjc4Pld5Nm\CCjczDj[YxtKH[rYXLpcIl1gSCjZoTldkA1QCCqcoOgZpkhTkGFUzDpckBxemW\|ZX7j[UBw\iCDUEG1NVAtKHqYQVSt[o1s	NX\nflNsRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMU[0NFgxODhpPkG2OFA5ODB6PD;hQi=>
Jurkat	MmfhR4VtdCCmZXH0bEBie3OjeR?=		M4fP[lQ5KGi{cx?=		NFzYRYhKdmirYnn0bY9vKG:oIHTlZZRpKHKnY3XweI9zKHOrZ37hcIlv\yCvZXTpZZRm\CCwZXPyc5B1d3SrYzDj[YxtKGSnYYToJIlvKGi3bXHuJGp2emujdDDj[YxteyCmZX\pZ4lmdnRiaX6gSmFFTCCjbnSg[ZhxemW\|c3nu[{BTUVBiS{S1UUBufXSjboSgZZN{\XO\|ZXSgZZMh[2WubDD2bYFjcWyrdImgZYZ1\XJiNEigbJJ{KGK7IF\BR3MhcW5icILld4Vv[2Vib3[gRXAyPTFyLDD6WmFFNW[vax?=	MmXGQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOTZ2MEiwNFgoRjF4NEC4NFA5RC:jPh?=
Jurkat	Mm\CR4VtdCCmZXH0bEBie3OjeR?=		NH3wR2E1QCCqcoO=		MkjUTY5pcWKrdHnvckBw\iCmZXH0bEBz\WOncITvdkB{cWewYXzpcochdWWmaXH0[YQhdmWlcn;weI91cWNiY3XscEBl\WG2aDDpckBpfW2jbjDKeZJs[XRiY3XscJMh\GWoaXPp[Y51KGmwIF\BSGQh[W6mIHX4dJJme3OrbnegVmlRKGurbnHz[UBld22jaX6gZZN{\XO\|ZXSgZZMh[2WubDD2bYFjcWyrdImgZYZ1\XJiNEigbJJ{KGK7IF\BR3MhcW5icILld4Vv[2Vib3[gRXAyPTFyLDD6WmFFNW[vax?=	MXS8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8yPjRyOECwPEc,OTZ2MEiwNFg9N2F-
Jurkat	NH3xd\|JE\WyuIHTlZZRpKGG\|c3H5		MXe0PEBpenN?		Mn32TY5pcWKrdHnvckBw\iCmZXH0bEBz\WOncITvdkB{cWewYXzpcochdWWmaXH0[YQhdmWlcn;weI91cWNiY3XscEBl\WG2aDDpckBpfW2jbjDKeZJs[XRiY3XscJMh\GWoaXPp[Y51KGmwIF\BSGQh[W6mIHX4dJJme3OrbnegSmtDWDF{LXLhd4VlKGSrbXXybZpifGmxbjDkc41icW5iYYPz[ZN{\WRiYYOgZ4VtdCC4aXHibYxqfHliYX\0[ZIhPDhiaILzJIJ6KE[DQ2OgbY4heHKnc3XuZ4Uhd2ZiQWCxOVEx	NXvZNFh7RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMU[0NFgxODhpPkG2OFA5ODB6PD;hQi=>
Jurkat	NHjESHNE\WyuIHTlZZRpKGG\|c3H5		Mmr0OFghcHK\|		MWjJcohq[mm2aX;uJI9nKGSnYYToJJJm[2WydH;yJJNq\26jbHnu[{Bu\WSrYYTl[EBv\WO{b4D0c5Rq[yClZXzsJIRm[XSqIHnuJIh2dWGwIFr1dotifCClZXzsd{Bl\W[rY3nlcpQhcW5iRlHESEBidmRiZYjwdoV{e2mwZzDSTXAhc2mwYYPlJIF{e2W\|c3XkJIF{KGOnbHygeoli[mmuaYT5JIFnfGW{IES4JIhzeyCkeTDGRWNUKGmwIIDy[ZNmdmOnIH;mJGFROTVzMB?=	M{P2OVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzF4NEC4NFA5Lz5zNkSwPFAxQDxxYU6=
Jurkat	M2fhT2NmdGxiZHXheIgh[XO\|YYm=		MlHJOFghcHK\|		MXfJcohq[mm2aX;uJI9nKGSnYYToJJJm[2WydH;yJJNq\26jbHnu[{Bu\WSrYYTl[EBv\WO{b4D0c5Rq[yClZXzsJIRm[XSqIHnuJIh2dWGwIFr1dotifCClZXzsd{Bl\W[rY3nlcpQhcW5iRlHESEBidmRiZYjwdoV{e2mwZzDSTXAhUzR3TTDteZRidnRiYYPz[ZN{\WRiYYOgZ4VtdCC4aXHibYxqfHliYX\0[ZIhPDhiaILzJIJ6KE[DQ2OgbY4heHKnc3XuZ4Uhd2ZiQWCxOVEx	NUfYSXdsRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMU[0NFgxODhpPkG2OFA5ODB6PD;hQi=>
Jurkat	MVfD[YxtKGSnYYToJIF{e2G7		M4XMd\|Q5KGi{cx?=		M4T5fmlvcGmkaYTpc44hd2ZiZHXheIghemWlZYD0c5Ihe2mpbnHsbY5oKG2nZHnheIVlKG6nY4LvdJRwfGmlIHPlcIwh\GWjdHigbY4hcHWvYX6gTpVzc2G2IHPlcIx{KGSnZnnjbYVvfCCrbjDGRWRFKGGwZDDlfJBz\XO\|aX7nJHJKWCCtaX7hd4Uh\G:vYXnuJIF{e2W\|c3XkJIF{KGOnbHygeoli[mmuaYT5JIFnfGW{IES4JIhzeyCkeTDGRWNUKGmwIIDy[ZNmdmOnIH;mJGFROTVzMB?=	MmLzQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOTZ2MEiwNFgoRjF4NEC4NFA5RC:jPh?=
Sf9	NGjMSmFHfW6ldHnvckBie3OjeR?=				MkDkTY5pcWKrdHnvckBw\iCqdX3hckBTUVBzIFu0OW0hdXW2YX70JIF2fG:yaH;zdIhwenmuYYTpc44h\XiycnXzd4VlKGmwIGPmPUBk\Wyucx?=	MlTVQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOTh2MEi3NVMoRjF6NEC4O\|E{RC:jPh?=
Jurkat	M1npfWN6fG:ycn;0[YN1cX[nIHHzd4F6	MlK1N\|AhfU1?	NIXEXGUyKGi{		NIrDb45EgXSxcILveIVkfGm4ZTDhZ5Rqfmm2eTDh[4FqdnO2IF\hd2wucW6mdXPl[EBv\WO{b4D0c5NqeyCrbjDoeY1idiCMdYLrZZQh[2WubIOgZZN{\XO\|ZXSgZZMhcW6lcnXhd4UhcW5iY3XscEB3cWGkaXzpeJkh[XRiM{CgeW0hcW6ldXLheIVlKG[xcjCxJIhzKG[xbHzve4VlKGK7IF\hd2whe3SrbYXsZZRqd25ibXXhd5Vz\WRiYX\0[ZIhOjBiaILzJIJ6KEGuYX3hdkBjdHWnIHHzd4F6	NGixWVc9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{OUW0NVM2Pyd-Mkm1OFE{PTd:L3G+
Jurkat	MlfZR5l1d3C{b4TlZ5RqfmViYYPzZZk>	NFTlPFg{OCC3TR?=	MVKxJIhz		NHnOb5VEgXSxcILveIVkfGm4ZTDhZ5Rqfmm2eTDh[4FqdnO2IFPIXE1qdmS3Y3XkJI5m[3KxcITvd4l{KGmwIHj1cYFvKEq3cnvheEBk\WyuczDhd5Nme3OnZDDhd{BqdmO{ZXHz[UBqdiClZXzsJJZq[WKrbHn0fUBifCB\|MDD1UUBqdmO3YnH0[YQh\m:{IEGgbJIh\m:ubH;3[YQh[nliQ1jYJJN1cW23bHH0bY9vKGK7IFHsZY1ieiCkbIXlJIF{e2G7	NVzEe3RZRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkm1OFE{PTdpPkK5OVQyOzV5PD;hQi=>
Jurkat	NFi3dXFEgXSxcILveIVkfGm4ZTDhd5NigQ>?	NXPNPYZ7OzBidV2=	MV:xJIhz		MXnDfZRweHKxdHXjeIl3\SCjY4Tpeol1gSCjZ3HpcpN1KFpvVlHEMYlv\HWlZXSgcoVkem:ydH;zbZMhcW5iaIXtZY4hUnW{a3H0JINmdGy\|IHHzd4V{e2WmIHHzJIlv[3KnYYPlJIlvKGOnbHygeoli[mmuaYT5JIF1KDNyIIXNJIlv[3WkYYTl[EBnd3JiMTDodkBnd2yub4fl[EBjgSCcLW\BSEB{fGmvdXzheIlwdiCkeTDBcIFu[XJiYnz1[UBie3OjeR?=	Ml\QQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjl3NEGzOVcoRjJ7NUSxN\|U4RC:jPh?=
Jurkat	NGXKNYZEgXSxcILveIVkfGm4ZTDhd5NigQ>?	M3q3U\|MxKHWP	M{PwTlEhcHJ?		NU\rdJVJS3m2b4Dyc5Rm[3SrdnWgZYN1cX[rdImgZYdicW6\|dDDGZZNNNWmwZIXj[YQhdmWlcn;weI9{cXNiaX6gbJVu[W5iSoXyb4F1KGOnbHzzJIF{e2W\|c3XkJIF{KGmwY4LlZZNmKGmwIHPlcIwhfmmjYnnsbZR6KGG2IEOwJJVOKGmwY4XiZZRm\CCob4KgNUBpeiCob3zsc5dm\CCkeTDGZZNNKHO2aX31cIF1cW:wIH3lZZN2emWmIHHmeIVzKDJyIHjyd{BjgSCyaHHz[UBkd262cnHzeEBucWO{b4Pjc5B6	NVrNW297RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkm1OFE{PTdpPkK5OVQyOzV5PD;hQi=>
Jurkat	MV7DfZRweHKxdHXjeIl3\SCjc4PhfS=>	MW[zNEB2VQ>?	MWKxJIhz		M{K0[GN6fG:ycn;0[YN1cX[nIHHjeIl3cXS7IHHnZYlve3RiQ1jYMYlv\HWlZXSgcoVkem:ydH;zbZMhcW5iaIXtZY4hUnW{a3H0JINmdGy\|IHHzd4V{e2WmIHHzJIlv[3KnYYPlJIlvKGOnbHygeoli[mmuaYT5JIF1KDNyIIXNJIlv[3WkYYTl[EBnd3JiMTDodkBnd2yub4fl[EBjgSCFSGigd5RqdXWuYYTpc44h[nlicHjhd4Uh[2:wdILhd5QhdWmlcn;zZ49xgQ>?	M4LseVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ7NUSxN\|U4Lz5{OUW0NVM2PzxxYU6=
Jurkat	MlrDR5l1d3C{b4TlZ5RqfmViYYPzZZk>	M2S5UlMxKHWP	NXfGcXlYOSCqch?=		M3TRRmN6fG:ycn;0[YN1cX[nIHHjeIl3cXS7IHHnZYlve3RiWj3WRWQucW6mdXPl[EBv\WO{b4D0c5NqeyCrbjDoeY1idiCMdYLrZZQh[2WubIOgZZN{\XO\|ZXSgZZMhcW6lcnXhd4UhcW5iY3XscEB3cWGkaXzpeJkh[XRiM{CgeW0hcW6ldXLheIVlKG[xcjCxJIhzKG[xbHzve4VlKGK7IGqtWmFFKHO2aX31cIF1cW:wIHL5JJBp[XOnIHPvcpRz[XO2IH3pZ5Jwe2OxcIm=	NWPRfHBtRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkm1OFE{PTdpPkK5OVQyOzV5PD;hQi=>

... Click to View More Cell Line Experimental Data

Assay

Methods	Test Index	PMID
Immunofluorescence	RIP1 / RIP3 ; PubMed: 30462730 PLoS One Immunofluorscence data showed an increased expression of RIP1 and RIP3 in Pg-LPS group and an eminent reduction of RIP1 in the Pg-LPS+Nec-1 group.	30462730

Protocol

Kinase Assay:

^[1]

- Collapse

RIP1 kinase assay:

Phosphorylation of RIP1 requires its kinase activity. Expression constructs of FLAGtagged wild-type (WT) or a kinase-inactive pointmutant of RIP1 (K45M) are are transfected into 293T cells and RIP1 kinase assay is performed as described in the Methods in the presence of [γ-³²P]ATP for 30 min at 30℃. Samples are subjected to SDS-PAGE and RIP1 band is visualized by autoradiography. Relative intensities of radioactive bands are quantified and are shown (ratio) in this and all other autoradiographs. In parallel to kinase reactions, a sample of beads is subjected to western blot analysis using anti-RIP1 antibody to ensure equal protein amounts in kinase reactions.

Cell Research:

^[2]

- Collapse

Cell lines: Jurkat, BALB/c 3T3, SV40-transformed MEF, L929
Concentrations: 0.01-100 μM
Incubation Time: --
Method:
Cells are seeded in 96-well plates (white plates for luminescent assays; black plates for fluorescent assays; clear plates for MTT assay) at the density of 5,000-10,000 cells per well for adherent cells or 20,000-50,000 cells per well for suspension cells in 100 μl of the appropriate phenol red-free media. After incubation, we determined cell viability using one of the following methods. For the ATP assay, we used luminescence-based commercial kits and analyzed luminescence using a Wallac Victor II plate reader. For Sytox assay, we incubated cells with 1 μM Sytox Green reagent for 30 min at 37℃, and then performed fluorescent reading. Subsequently, we added 5 μl of 20% Triton X-100 solution into each well to produce maximal lysis and incubated cells for 1 h at 37℃, then performed the second reading. We calculated the ratio of values before and after Triton treatment and normalized it to the relevant controls not subjected to cytotoxic stimuli, as indicated in figure legends. For the MTT assay, we used the CellTiter 96 AQueous Non-Radioactive Cell Proliferation Assay kit. For PI exclusion assays, we added 2 μg/ml PI into the medium and immediately analyzed samples using FACSCalibur. For PI-annexin V assay we used the ApoAlert Annexin V-EGFP Apoptosis Kit. For DioC6 staining, we incubated cells with 40 nM DiOC₆ for 30 min at 37 ℃, washed once and analyzed in FACSCalibur. For ROS analysis, we incubated cells with 5 μM dihydroethidium for 30 min at 37 ℃, washed once and analyzed in FACSCalibur. EM analyses are performed at the Harvard Medical School EM facility. We acquired bright-field images of the cells using an Axiovert 200 microscope.

(Only for Reference)

References

Solubility (25°C)

In vitro	DMSO	51 mg/mL warmed (196.66 mM)
	Water	Insoluble
	Ethanol	Insoluble
In vivo	Add solvents to the product individually and in order(Data is from Selleck tests instead of citations): 5% DMSO+45% PEG 300+ddH2O For best results, use promptly after mixing.	10mg/mL

* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.

Chemical Information Download Necrostatin-1 SDF

Molecular Weight	259.33
Formula	C₁₃H₁₃N₃OS
CAS No.	4311-88-0
Storage	3 years-20°C powder 2 years-80°C in solvent
Synonyms	Nec-1
Smiles	CN1C(=O)C(NC1=S)CC2=CNC3=CC=CC=C32

In vivo Formulation Calculator (Clear solution)

Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)

Dosage

mg/kg

Average weight of animals

Dosing volume per animal

Number of animals

Step 2: Enter the in vivo formulation (This is only the calculator, not formulation. Please contact us first if there is no in vivo formulation at the solubility Section.)

% DMSO+ % + % Tween 80+ % ddH₂O

Calculate Reset

Calculation results:

Working concentration： mg/ml；

Method for preparing DMSO master liquid: ： mg drug pre-dissolved in μL DMSO (Master liquid concentration mg/mL， Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug. )

Method for preparing in vivo formulation：Take μL DMSO master liquid, next addμL PEG300， mix and clarify, next addμL Tween 80，mix and clarify, next add μL ddH₂O，mix and clarify.

Note：1.Please make sure the liquid is clear before adding the next solvent.
2.Be sure to add the solvent(s) in order. You must ensure that the solution obtained, in the previous addition, is a clear solution before proceeding to add the next solvent. Physical methods such as vortex, ultrasound or hot water bath can be used to aid dissolving.

Bio Calculators

Molarity Calculator

Calculate the mass, volume or concentration required for a solution. The Selleck molarity calculator is based on the following equation:

Mass (mg) = Concentration (mM) × Volume (mL) × Molecular Weight (g/mol)

*When preparing stock solutions, please always use the batch-specific molecular weight of the product found on the via label and SDS / COA (available on product pages).

Dilution Calculator

Calculate the dilution required to prepare a stock solution. The Selleck dilution calculator is based on the following equation:

Concentration _(start) x Volume _(start) = Concentration _(final) x Volume _(final)

This equation is commonly abbreviated as: C1V1 = C2V2 ( Input Output )

* When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and SDS / COA (available online).

The Serial Dilution Calculator Equation

Serial Dilutions
Concertration (start):
Dilution-folds:

Computed Result

C1=C0/X	C1:	LOG(C1):
C2=C1/X	C2:	LOG(C2):
C3=C2/X	C3:	LOG(C3):
C4=C3/X	C4:	LOG(C4):
C5=C4/X	C5:	LOG(C5):
C6=C5/X	C6:	LOG(C6):
C7=C6/X	C7:	LOG(C7):
C8=C7/X	C8:	LOG(C8):

Molecular Weight Calculator

Enter the chemical formula of a compound to calculate its molar mass and elemental composition:

Tip: Chemical formula is case sensitive. C10H16N2O2 c10h16n2o2

Instructions to calculate molar mass (molecular weight) of a chemical compound:

To calculate molar mass of a chemical compound, please enter its chemical formula and click 'Calculate'.

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molecular mass (molecular weight) is the mass of one molecule of a substance and is expressed in the unified atomic mass units (u). (1 u is equal to 1/12 the mass of one atom of carbon-12)
Molar mass (molar weight) is the mass of one mole of a substance and is expressed in g/mol.

Molarity Calculator

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

Choose Your Country or Region

By Signaling Pathways

By product type

Necrostatin-1